Testing effectiveness (Phase 2)Study completedNCT00316264
What this trial is testing
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season
Who this might be right for
Respiratory Syncytial Virus InfectionsChronic Lung Disease and <= 24 Months of Age orPremature With Gestational Age <=35 Weeks and <=6 Months of Age
MedImmune LLC 260